Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Molecular Characterization and Mortality From Breast Cancer in Men.

Massarweh SA, Sledge GW, Miller DP, McCullough D, Petkov VI, Shak S.

J Clin Oncol. 2018 May 10;36(14):1396-1404. doi: 10.1200/JCO.2017.76.8861. Epub 2018 Mar 27.

2.

Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers.

Williams MM, Lee L, Werfel T, Joly MMM, Hicks DJ, Rahman B, Elion D, McKernan C, Sanchez V, Estrada MV, Massarweh S, Elledge R, Duvall C, Cook RS.

Cell Death Dis. 2018 Jan 17;9(2):21. doi: 10.1038/s41419-017-0072-x.

3.

Endocrine therapy and strategies to overcome therapeutic resistance in breast cancer.

Mancuso MR, Massarweh SA.

Curr Probl Cancer. 2016 Mar - Aug;40(2-4):95-105. doi: 10.1016/j.currproblcancer.2016.09.001. Epub 2016 Sep 17. Review.

PMID:
27839747
4.

Special considerations in the evaluation and management of breast cancer in men.

Massarweh SA, Choi GL.

Curr Probl Cancer. 2016 Mar - Aug;40(2-4):163-171. doi: 10.1016/j.currproblcancer.2016.09.003. Epub 2016 Sep 17. Review.

PMID:
27793424
5.

Introduction to special issue on breast cancer.

Massarweh SA.

Curr Probl Cancer. 2016 Mar - Aug;40(2-4):93-94. doi: 10.1016/j.currproblcancer.2016.09.010. Epub 2016 Sep 23. No abstract available.

PMID:
27793423
6.

Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance.

Malorni L, Giuliano M, Migliaccio I, Wang T, Creighton CJ, Lupien M, Fu X, Hilsenbeck SG, Healy N, De Angelis C, Mazumdar A, Trivedi MV, Massarweh S, Gutierrez C, De Placido S, Jeselsohn R, Brown M, Brown PH, Osborne CK, Schiff R.

Mol Cancer Res. 2016 May;14(5):470-81. doi: 10.1158/1541-7786.MCR-15-0423. Epub 2016 Mar 10.

7.

Blastic plasmacytoid dendritic cell neoplasm with extensive cutaneous and central nervous system involvement.

Saeed H, Awasthi M, Al-Qaisi A, Massarweh S.

Rare Tumors. 2014 Oct 27;6(4):5474. doi: 10.4081/rt.2014.5474. eCollection 2014 Oct 27.

8.

Impact of estrogen receptor (ER) and human epidermal growth factor receptor-2 (HER2) co-expression on breast cancer disease characteristics: implications for tumor biology and research.

Alqaisi A, Chen L, Romond E, Chambers M, Stevens M, Pasley G, Awasthi M, Massarweh S.

Breast Cancer Res Treat. 2014 Nov;148(2):437-44. doi: 10.1007/s10549-014-3145-x. Epub 2014 Sep 26.

PMID:
25257728
9.

Everolimus-induced hematologic changes in patients with metastatic breast cancer.

Chen A, Chen L, Al-Qaisi A, Romond E, Awasthi M, Kadamyan-Melkumyan V, Massarweh S.

Clin Breast Cancer. 2015 Feb;15(1):48-53. doi: 10.1016/j.clbc.2014.07.002. Epub 2014 Aug 15.

PMID:
25199576
10.

Metastatic angiosarcoma and kasabach-merritt syndrome.

Massarweh S, Munis A, Karabakhtsian R, Romond E, Moss J.

Rare Tumors. 2014 Jun 13;6(2):5366. doi: 10.4081/rt.2014.5366. eCollection 2014 May 13.

11.

Impact of adding the multikinase inhibitor sorafenib to endocrine therapy in metastatic estrogen receptor-positive breast cancer.

Massarweh S, Moss J, Wang C, Romond E, Slone S, Weiss H, Karabakhtsian RG, Napier D, Black EP.

Future Oncol. 2014 Dec;10(15):2435-48. doi: 10.2217/fon.14.99.

12.

A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure.

Massarweh S, Romond E, Black EP, Van Meter E, Shelton B, Kadamyan-Melkumian V, Stevens M, Elledge R.

Breast Cancer Res Treat. 2014 Jan;143(2):325-32. doi: 10.1007/s10549-013-2810-9. Epub 2013 Dec 11. Erratum in: Breast Cancer Res Treat. 2015 Jan;149(2):565.

PMID:
24327334
13.

ErbB3 downregulation enhances luminal breast tumor response to antiestrogens.

Morrison MM, Hutchinson K, Williams MM, Stanford JC, Balko JM, Young C, Kuba MG, Sánchez V, Williams AJ, Hicks DJ, Arteaga CL, Prat A, Perou CM, Earp HS, Massarweh S, Cook RS.

J Clin Invest. 2013 Oct;123(10):4329-43. doi: 10.1172/JCI66764. Epub 2013 Sep 3.

14.

A prognostic model of early breast cancer relapse after standard adjuvant therapy and comparison with metastatic disease on initial presentation.

Chen L, Romond E, Chokshi S, Saeed H, Hodskins J, Stevens M, Pasley G, Weiss H, Massarweh S.

Breast Cancer Res Treat. 2012 Nov;136(2):565-72. doi: 10.1007/s10549-012-2265-4. Epub 2012 Oct 4.

PMID:
23053651
15.

Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies.

Chen AC, Migliaccio I, Rimawi M, Lopez-Tarruella S, Creighton CJ, Massarweh S, Huang C, Wang YC, Batra SK, Gutierrez MC, Osborne CK, Schiff R.

Breast Cancer Res Treat. 2012 Jul;134(2):583-93. doi: 10.1007/s10549-012-2082-9. Epub 2012 May 29.

16.

Pathologic changes in breast cancer after anti-estrogen therapy.

Samarnthai N, Elledge R, Prihoda TJ, Huang J, Massarweh S, Yeh IT.

Breast J. 2012 Jul-Aug;18(4):362-6. doi: 10.1111/j.1524-4741.2012.01251.x. Epub 2012 May 23.

PMID:
22616615
17.

Everolimus in HR-positive advanced breast cancer.

Massarweh S, Croley J, Weiss H.

N Engl J Med. 2012 May 3;366(18):1738-9; author reply 1739-40. doi: 10.1056/NEJMc1202719. No abstract available.

18.

Images in clinical medicine. Hypertrophic pulmonary osteoarthropathy and tripe palms.

Saeed H, Massarweh S.

N Engl J Med. 2012 Jan 26;366(4):360. doi: 10.1056/NEJMicm1110862. No abstract available.

19.

Resolution of extensive leptomeningeal metastasis and clinical spinal cord compression from breast cancer using weekly docetaxel chemotherapy.

Wilson B, Sapp C, Abdeen G, Kamona A, Massarweh S.

Breast Cancer Res Treat. 2012 Jan;131(1):343-6. doi: 10.1007/s10549-011-1825-3. Epub 2011 Oct 26.

PMID:
22037782
20.

A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer.

Massarweh S, Tham YL, Huang J, Sexton K, Weiss H, Tsimelzon A, Beyer A, Rimawi M, Cai WY, Hilsenbeck S, Fuqua S, Elledge R.

Breast Cancer Res Treat. 2011 Oct;129(3):819-27. doi: 10.1007/s10549-011-1679-8. Epub 2011 Jul 27.

21.

Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts.

Rimawi MF, Wiechmann LS, Wang YC, Huang C, Migliaccio I, Wu MF, Gutierrez C, Hilsenbeck SG, Arpino G, Massarweh S, Ward R, Soliz R, Osborne CK, Schiff R.

Clin Cancer Res. 2011 Mar 15;17(6):1351-61. doi: 10.1158/1078-0432.CCR-10-1905. Epub 2010 Dec 7.

22.

Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts.

Creighton CJ, Massarweh S, Huang S, Tsimelzon A, Hilsenbeck SG, Osborne CK, Shou J, Malorni L, Schiff R.

Cancer Res. 2008 Sep 15;68(18):7493-501. doi: 10.1158/0008-5472.CAN-08-1404.

23.

Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function.

Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S, Weiss H, Rimawi M, Schiff R.

Cancer Res. 2008 Feb 1;68(3):826-33. doi: 10.1158/0008-5472.CAN-07-2707.

24.

Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy.

Arpino G, Gutierrez C, Weiss H, Rimawi M, Massarweh S, Bharwani L, De Placido S, Osborne CK, Schiff R.

J Natl Cancer Inst. 2007 May 2;99(9):694-705.

PMID:
17470737
25.

Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities.

Massarweh S, Schiff R.

Clin Cancer Res. 2007 Apr 1;13(7):1950-4. Review.

26.

Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk.

Massarweh S, Schiff R.

Endocr Relat Cancer. 2006 Dec;13 Suppl 1:S15-24. Review.

27.

Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer.

Massarweh S, Osborne CK, Jiang S, Wakeling AE, Rimawi M, Mohsin SK, Hilsenbeck S, Schiff R.

Cancer Res. 2006 Aug 15;66(16):8266-73.

28.

Prevalence of hormone receptors and HER2/neu in breast cancer cases in Jordan.

Sughayer MA, Al-Khawaja MM, Massarweh S, Al-Masri M.

Pathol Oncol Res. 2006;12(2):83-6. Epub 2006 Jun 24.

29.

Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators.

Schiff R, Massarweh SA, Shou J, Bharwani L, Arpino G, Rimawi M, Osborne CK.

Cancer Chemother Pharmacol. 2005 Nov;56 Suppl 1:10-20. Review.

PMID:
16273359
30.

Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer.

Osborne CK, Shou J, Massarweh S, Schiff R.

Clin Cancer Res. 2005 Jan 15;11(2 Pt 2):865s-70s. Review.

31.

Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.

Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R.

J Natl Cancer Inst. 2004 Jun 16;96(12):926-35.

PMID:
15199112
32.

Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance.

Schiff R, Massarweh SA, Shou J, Bharwani L, Mohsin SK, Osborne CK.

Clin Cancer Res. 2004 Jan 1;10(1 Pt 2):331S-6S.

33.

Small-cell cancers, and an unusual reaction to chemotherapy. Case 2. Synchronous renal cell carcinoma and limited-stage small-cell lung cancer.

Massarweh S, Lewitton M, Popat U, Lynch GR.

J Clin Oncol. 2003 Jun 15;21(12):2439-40. No abstract available.

PMID:
12805345
34.

HIV-related Hodgkin's disease with central nervous system involvement and association with Epstein-Barr virus.

Massarweh S, Udden MM, Shahab I, Kroll M, Sears DA, Lynch GR, Teh BS, Lu HH.

Am J Hematol. 2003 Mar;72(3):216-9.

35.

Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response.

Schiff R, Massarweh S, Shou J, Osborne CK.

Clin Cancer Res. 2003 Jan;9(1 Pt 2):447S-54S. Review.

36.

Erythroblast island.

Massarweh S, Lynch EC.

Haematologica. 2002 Apr;87(4):EIM10. No abstract available.

PMID:
11940497
37.

Unusual sites of malignancy: case 3. Solitary splenic metastasis in lung cancer with spontaneous rupture.

Massarweh S, Dhingra H.

J Clin Oncol. 2001 Mar 1;19(5):1574-5. No abstract available.

PMID:
11230502

Supplemental Content

Loading ...
Support Center